Fortrea (NASDAQ:FTRE – Get Free Report) is one of 46 publicly-traded companies in the “Medical laboratories” industry, but how does it weigh in compared to its rivals? We will compare Fortrea to similar businesses based on the strength of its dividends, analyst recommendations, risk, institutional ownership, profitability, valuation and earnings.
Analyst Recommendations
This is a summary of current ratings for Fortrea and its rivals, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Fortrea | 1 | 2 | 5 | 1 | 2.67 |
Fortrea Competitors | 308 | 1192 | 2081 | 33 | 2.51 |
Fortrea presently has a consensus target price of $34.43, suggesting a potential upside of 34.75%. As a group, “Medical laboratories” companies have a potential upside of 23.17%. Given Fortrea’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Fortrea is more favorable than its rivals.
Profitability
Net Margins | Return on Equity | Return on Assets | |
Fortrea | -4.11% | 4.76% | 1.87% |
Fortrea Competitors | -3,335.19% | -1,311.65% | -38.81% |
Insider and Institutional Ownership
47.5% of shares of all “Medical laboratories” companies are held by institutional investors. 0.1% of Fortrea shares are held by insiders. Comparatively, 18.9% of shares of all “Medical laboratories” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Fortrea and its rivals revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Fortrea | $3.11 billion | -$3.40 million | -18.38 |
Fortrea Competitors | $995.74 million | -$125.17 million | 4.29 |
Fortrea has higher revenue and earnings than its rivals. Fortrea is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Summary
Fortrea beats its rivals on 8 of the 12 factors compared.
About Fortrea
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with MarketBeat.com's FREE daily email newsletter.